Unproven Therapies for Diabetes and Their Implications

Advances in Therapy

Volumn 34, Issue 1, 2017, Pages 60-77

  Kesavadev, Jothydev ^a   Saboo, Banshi ^b   Sadikot, Shaukat ^c   Das, Ashok Kumar ^d   Joshi, Shashank ^e   Chawla, Rajeev ^f   Thacker, Hemant ^g   Shankar, Arun ^a   Ramachandran, Lakshmy ^a   Kalra, Sanjay ^h  

^a Jothydev's Diabetes and Research Center   (India)

^b Dia Care and Hormone Clinic   (India)

^c JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^d JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^e LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

^f North Delhi Diabetes Centre   (India)

^g Bhatia Hospital   (India)

^h India   (India)

Author keywords

Ayurveda; CAM; Complementary and alternative medicine; Diabetes; Herbal medicine; Supplements; TM; Traditional medicine

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; AYURVEDIC DRUG; BIGUANIDE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GALEGINE; GINSENOSIDE; GLIBENCLAMIDE; INSULIN; METFORMIN; MINERAL; NATURAL PRODUCT; PHENFORMIN; PROBIOTIC AGENT; SULFONYLUREA; VITAMIN;

ALLOPATHY; ALTERNATIVE MEDICINE; BOTANY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DIETARY SUPPLEMENT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH PRACTITIONER; HERB; HERBAL MEDICINE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MASSAGE; MEDICAL HISTORY; MEDITATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PATIENT COUNSELING; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SPIRITUAL HEALING; TRADITIONAL MEDICINE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; CHRONIC DISEASE; PROCEDURES;

CHRONIC DISEASE; COMPLEMENTARY THERAPIES; DIABETES MELLITUS; HUMANS;

EID: 84995785005     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0439-x     Document Type: Review

References (122)

1. Global report on diabetes. Geneva: World Health Organization; 2016.
2. IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2015.
3. Hirschler B. Diabetes now kills more than HIV, tuberculosis and malaria combined. The Huggington Post, The Times of India; 2015 [cited 2016 11.06.16]; Available from: http://www.huffingtonpost.com/entry/diabetes-deaths_us_5643e784e4b08cda348777bf?section=india.
4. Life expectancy increased by 5 years since 2000, but health inequalities persist. Geneva: World Health Organization, Observatory GH; 2016 19 May 2016 Report No.
5. Mishra S. Does modern medicine increase life-expectancy: quest for the moon rabbit? Indian Heart J. 2016;68(1):19–27.
6. Kesavadev J, Short K, Nair KS. Diabetes in old age: an emerging epidemic. J Assoc Physicians India. 2003;51:1083–94.
7. Ebbell B. The Papyrus Ebers, the Greatest Egyptian Medical Document. Copenhagen; Oxford University Press: London; 1937.
8. Poretsky L. Principles of diabetes mellitus. 2nd ed. Springer; 2010. doi:10.1007/978-0-387-09841-8.
9. Papaspyros NS. The history of diabetes mellitus. 2nd ed. G. Thieme; 1964. p. 213.
10. Sanders LJ. From Thebes to Toronto and the 21st century: an incredible journey. Diabetes Spectr. 2002;15(1):56–60.
11. Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002;23(4):373–8.
12. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254–64 [Epub 2008/09/20].
13. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88 [Epub 2013/01/11].
14. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9.
15. Nouwen A, Nefs G, Caramlau I, et al. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care. 2011;34(3):752–62 [Epub 2011/03/02].
16. Adeniyi AF, Adeleye JO, Adeniyi CY. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Curr Diabetes Rev. 2010;6(4):201–6.
17. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complicat. 2011;25(2):129–36.
18. Complementary, Alternative, or Integrative health: what’s in a name? USA: National Center for Complementary and Integrative Health; 2016 [updated June 2016 cited 2016 27.09.16]; Available from: https://nccih.nih.gov/health/integrative-health.
19. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National Health Stat Rep. 2015;79:1.
20. Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4–17 years in the United States: National Health Interview Survey, 2007–2012. National Health Stat Rep. 2015;78:1.
21. Koren R, Lerner A, Tirosh A, et al. The use of complementary and alternative medicine in hospitalized patients with type 2 diabetes mellitus in Israel. J Alternat Complement Med. 2015;21(7):395–400.
22. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279(19):1548–53.
23. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Semin Integr Med. 2004;2(2):54–71.
24. Naja F, Mousa D, Alameddine M, Shoaib H, Itani L, Mourad Y. Prevalence and correlates of complementary and alternative medicine use among diabetic patients in Beirut, Lebanon: a cross-sectional study. BMC Complement Alternat Med. 2014;14(1):1.
25. Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther. 2005;4(4):274–86.
26. Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002;25(2):324–9.
27. H-Y Chang, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people living with diabetes: literature review. J Adv Nurs. 2007;58(4):307–19.
28. Birdee GS, Yeh G. Complementary and alternative medicine therapies for diabetes: a clinical review. Clin Diabetes. 2010;28(4):147–55.
29. Chacko E. Culture and therapy: complementary strategies for the treatment of type-2 diabetes in an urban setting in Kerala, India. Soc Sci Med. 2003;56(5):1087–98.
30. American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80 [Epub 2013/12/21].
31. Grant SJ, Bensoussan A, Chang D, et al. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. 2009;4(4):CD006690. doi:10.1002/14651858.CD006690.pub2.
32. Sridharan K, Mohan R, Ramaratnam S, Panneerselvam D. Ayurvedic treatments for diabetes mellitus. Cochrane Database Syst Rev. 2011;(12):CD008288. doi:10.1002/14651858.CD008288.pub2.
33. Bauml JM, Chokshi S, Schapira MM, et al. Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey. Cancer. 2015;121(14):2431–8.
34. Kim SH, Shin DW, Nam Y-S, et al. Expected and perceived efficacy of complementary and alternative medicine: a comparison views of patients with cancer and oncologists. Complement Ther Med. 2016;28:29–36.
35. McCarty RL, Weber WJ, Loots B, et al. Complementary and alternative medicine use and quality of life in pediatric diabetes. J Alternat Complement Med. 2010;16(2):165–73.
36. Spinks J, Johnston D, Hollingsworth B. Complementary and alternative medicine (CAM) use and quality of life in people with type 2 diabetes and/or cardiovascular disease. Complement Ther Med. 2014;22(1):107–15.
37. Alfian S, Sukandar H, Arisanti N, Abdulah R. Complementary and alternative medicine use decreases adherence to prescribed medication in diabetes patients. Ann Trop Med Public Health. 2016;9(3):174–9.
38. Guthrie D, Guthrie R. Management of diabetes mellitus: a guide to the pattern approach, 6 edn. New York: Springer Publishing Company, LLC; 2008, p 544.
39. White JR, Jr., Hartman J, Campbell RK. Drug interactions in diabetic patients. The risk of losing glycemic control. Postgrad Med. 1993;93(3):131–2, 5–9 [Epub 1993/02/15].
40. Niggemann B, Grüber C. Unconventional and conventional medicine: who should learn from whom? Pediatr Allergy Immunol. 2003;14(3):149–55.
41. Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: part 2: regulatory and safety concerns and proposed governmental policy changes with respect to dietary supplements. Pharm Ther. 2010;35(9):514.
42. Rehman SU, Choi MS, Choe K, Yoo HH. Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, importance, and management. Arch Pharm Res. 2015;38(7):1281–98.
43. Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513–8.
44. Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutr Metab Cardiovasc Dis. 2005;15(3):149–60.
45. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927–41.
46. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs. 2009;69(13):1777–98.
47. Gardiner P, Phillips R, Shaughnessy AF. Herbal and dietary supplement–drug interactions in patients with chronic illnesses. Am Fam Physician. 2008;77(1):73–8.
48. Izzo AA. Herb–drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19(1):1–16.
49. Aslam M, Stockley I. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet. 1979;313(8116):607.
50. Gin H, Orgerie M, Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res. 1989;21(02):81–3.
51. Neugebauer G, Akpan W, Abshagen U. Interaction of guar with glibenclamide and bezafibrate. Beitr Infusionther Klin Ernahr. 1983;12:40.
52. Shane-McWhorter L. Complementary and alternative medicine (CAM) supplement use in people with diabetes: a clinician’s guide. Alexandria, Virginia: American Diabetes Association; 2007.
53. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med. 1998;339(12):847.
54. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US-and Indian-manufactured ayurvedic medicines sold via the internet. JAMA. 2008;300(8):915–23.
55. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci. 2002;23(3):136–9.
56. Goudie AM, Kaye JM. Contaminated medication precipitating hypoglycaemia. Med J Aust. 2001;175(5):256.
57. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37(4):344–50.
58. Ries CA, Sahud MA. Agranulocytosis caused by Chinese herbal medicines: dangers of medications containing aminopyrine and phenylbutazone. JAMA. 1975;231(4):352–5.
59. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. Drug Saf. 1997;17(5):342–56.
60. Lead Poisoning in pregnant women who used ayurvedic medications from India—New York City, 2011–2012. USA: Centers for Disease Control and Prevention; 2012 August 24. Report No.
61. Beigel Y, Ostfeld I, Schoenfeld N. A leading question. N Engl J Med. 1998;339(12):827–30.
62. Keen R, Deacon A, Delves H, Moreton J, Frost P. Indian herbal remedies for diabetes as a cause of lead poisoning. Postgrad Med J. 1994;70(820):113–4.
63. Pontifex AH, Garg AK. Lead poisoning from an Asian Indian folk remedy. Can Med Assoc J. 1985;133(12):1227.
64. Kulambil Padinjakara RN, Ashawesh K, Butt S, Nair R, Patel V. Herbal remedy for diabetes: two case reports. Exp Clin Endocrinol Diabetes. 2009;117(1):3–5 [Epub 2009/01/14].
65. FDA. Use caution with ayurvedic products USA 2008 [cited 2016 23/06]; Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm050798.htm.
66. Hardy ML, Coulter I, Venuturupalli S, et al. Ayurvedic interventions for diabetes mellitus: a systematic review. Evid Rep Technol Assess (Summ). 2001;(41):2.
67. Elder C. Ayurveda for diabetes mellitus: a review of the biomedical literature. Altern Ther Health Med. 2004;10(1):44.
68. Koh H-L, Woo S-O. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 2000;23(5):351–62.
69. Cosyns J-P, Jadoul M, Squifflet J-P, Wese F-X, de Strihou CVY. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis. 1999;33(6):1011–7.
70. Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–92.
71. Cosyns J-P. Aristolochic acid and ‘Chinese herbs nephropathy’. Drug Saf. 2003;26(1):33–48.
72. Ernst E. Life-threatening complications of spinal manipulation. Stroke. 2001;32(3):809–10.
73. Brettel H. Akupunktur als Todesursache. Munch Med Wochenschr. 1981;123(3):97–8.
74. Mazal DA, King T, Harvey J, Cohen J. Bilateral pneumothorax after acupuncture. N Engl J Med. 1980;302(24):1365.
75. Cheng TO. Cardiac tamponade following acupuncture. CHEST J. 2000;118(6):1836–7.
76. Kataoka H. Cardiac tamponade caused by penetration of an acupuncture needle into the right ventricle. J Thorac Cardiovasc Surg. 1997;114(4):674–6.
77. Kirchgatterer A, Schwarz CD, Holler E, Punzengruber C, Hartl P, Eber B. Cardiac tamponade following acupuncture. CHEST J. 2000;117(5):1510–1.
78. Peuker ET, White A, Ernst E, Pera F, Filler TJ. Traumatic complications of acupuncture: therapists need to know human anatomy. Arch Fam Med. 1999;8(6):553.
79. Ernst E, White A. Life-threatening adverse reactions after acupuncture? A systematic review. Pain. 1997;71(2):123–6.
80. Rampes H, James R. Complications of acupuncture. Acupunct Med. 1995;13(1):26–33.
81. Greenberg R. Corruption and culture increase diabetes deaths in India. India: The Huffington Post; 2014. http://www.huffingtonpost.in/entry/corruption-and-culture-in_b_5897042.
82. Chao Y-FC, Chen S-Y, Lan C, Lai J-S. The cardiorespiratory response and energy expenditure of Tai-Chi-Qui-Gong. Am J Chin Med. 2002;30(04):451–61.
83. Hagins M, Moore W, Rundle A. Does practicing hatha yoga satisfy recommendations for intensity of physical activity which improves and maintains health and cardiovascular fitness? BMC Complement Alternat Med. 2007;7(1):1.
84. Ospina MB, Bond K, Karkhaneh M, et al. Meditation practices for health: state of the research. Rockville, MD: Agency for Healthcare Research and Quality; 2007. https://www.ncbi.nlm.nih.gov/books/NBK38360/.
85. Aljasir B, Bryson M, Al-shehri B. Yoga practice for the management of type II diabetes mellitus in adults: a systematic review. Evid Based Complement Alternat Med. 2010;7(4):399–408.
86. Innes KE, Vincent HK. The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus: a systematic review. Evid Based Complement Alternat Med. 2007;4(4):469–86 [Epub 2008/01/30].
87. Lam P, Dennis SM, Diamond TH, Zwar N. Improving glycaemic and BP control in type 2 diabetes: the effectiveness of tai chi. Aust Fam Physician. 2008;37(10):884.
88. Lee M, Pittler M, Kim MS, Ernst E. Tai chi for Type 2 diabetes: a systematic review. Diabet Med. 2008;25(2):240–1.
89. Tsang T, Orr R, Lam P, Comino EJ, Singh MF. Health benefits of Tai Chi for older patients with type 2 diabetes: the “Move It for Diabetes Study”—a randomized controlled trial. Clin Interv Aging. 2007;2(3):429.
90. Tan AC, Mak JC. Complementary and alternative medicine in diabetes (CALMIND)—a prospective study. J Complement Integr Med. 2015;12(1):95–9 [Epub 2015/01/13].
91. Ezuruike UF, Prieto JM. The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations. J Ethnopharmacol. 2014;155(2):857–924.
92. American Diabetes A. Unproven therapies. Diabetes Care. 2004;27(Suppl 1):S135 [Epub 2003/12/25].
93. Debas HT, Laxminarayan R, Straus SE. Complementary and alternative medicine. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): Oxford University Press, New York; 2006.
94. Berman JD, Straus SE. Implementing a research agenda for complementary and alternative medicine. Annu Rev Med. 2004;55:239–54.
95. WHO. Research guidelines for evaluating the safety and efficacy of herbal medicines: Manila: WHO Regional Office for the Western Pacific; 1993.
96. WHO. Regulatory situation of herbal medicines: a worldwide review. Geneva: World Health Organization; 1998.
97. Singh A. Regulatory and pharmacological bases of ayurvedic formulations. CRC Press; 2016. 268 p. ISBN 9781498750967.
98. Misra A, Gulati S, Luthra A. Alternative medicines for diabetes in India: maximum hype, minimum science. Lancet Diabetes Endocrinol. 2016;4(4):302–3.
99. Mills SY. Regulation in complementary and alternative medicine. Br Med J. 2001;322(7279):158.
100. Bodeker G, Ong CK, Grundy C, Burford G, Shein K. WHO global atlas of traditional, complementary and alternative medicine. Kobe, Japan: WHO Centre for Health Development; 2005.
101. Ries NM, Fisher KJ. Increasing involvement of physicians in complementary and alternative medicine: Considerations of professional regulation and patient safety. Queen’s Law J. 2013–2014;39(1):273–300.
102. Drugs and Magic Remedies (Objectionable Advertisements) Act, Stat. 21 (30th April 1954, 1954).
103. Myers SP, Cheras PA. The other side of the coin: safety of complementary and alternative medicine. Med J Aust. 2004;181(4):222–5.
104. Osadebe PO, Odoh EU. Natural products as potential sources of antidiabetic drugs. Br J Pharmaceut Res. 2014;4(17):2075.
105. Oubre A, Carlson T, King S, Reaven G. From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia. 1997;40(5):614–7.
106. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8):1105–7 [Epub 2001/10/17].
107. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–8 [Epub 2004/12/30].
108. White JR. Apple trees to sodium glucose co-transporter Inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28(1):5–10.
109. Eng J, Kleinman W, Singh L, Singh G, Raufman J-P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–5.
110. Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012;59(4):464–71.
111. Leroux-Stewart J, Rabasa-Lhoret R, Chiasson J-L. α-Glucosidase inhibitors. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM, editors. International textbook of diabetes mellitus. 4th ed. Chichester, UK: Wiley; 2015. p. 673–85. doi:10.1002/9781118387658.ch45.
112. Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Randomized controlled trials of herbal interventions underreport important details of the intervention. J Clin Epidemiol. 2011;64(7):760–9.
113. Gagnier JJ, Boon H, Rochon P, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134–49.
114. Cohen K, Cerone P, Ruggiero R. Complementary/alternative medicine use: responsibilities and implications for pharmacy services. P AND T. 2002;27(9):440–7.
115. Kwan D, Hirschkorn K, Boon H. US and Canadian pharmacists’ attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review. BMC Complement Alternat Med. 2006;6(1):1.
116. MCNZ. Statement on complementary and alternative medicine; 2011. https://www.mcnz.org.nz/assets/News-and-Publications/Statements/Complementary-and-alternative-medicine.pdf.
117. Geil P, Shane-McWhorter L. Dietary supplements in the management of diabetes: potential risks and benefits. J Am Diet Assoc. 2008; 108(4 Suppl 1):S59–65.
118. DerMarderosian A, Beutler JA. The review of natural products: the most complete source of natural product information. Wolters Kluwer Health; 2010.
119. Shane-McWhorter L. Biological complementary therapies: a focus on botanical products in diabetes. Diabetes Spect. 2001;14(4):199–208.
120. Smith JD, Clinard VB. Natural products for the management of type 2 diabetes mellitus and comorbid conditions. J Am Pharm Assoc. 2014;54(5):e304–21.
121. Medagama AB, Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? Nutr J. 2014;13:102 [Epub 2014/10/22].
122. D’Huyvetter K. Complementary and alternative medicine in diabetes. In: Zazworsky D, Bolin JN, Gaubeca VB, editors. Handbook of diabetes management. Boston, MA: Springer US; 2005. p. 257–71.